July 16, 2009 - Highly Statistically Significant Defective Serum Copper Handling Found in Alzheimer’s Subjects - Subclinical Zinc Deficiency in Alzheimer’s Subjects Found - HartLab Introduced to International Alzheimer’s Community - Adeona Pharmaceuticals, Inc. (AMEX:AEN), a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population, announced that it presented results of a 90 subject prospective, blinded, observational clinical study to evaluate copper and zinc status in Alzheimer’s disease, Parkinson ’s disease and normal subjects. The results were presented at the 2009 International Conference on Alzheimer’s Disease (ICAD) in Vienna, Austria. Two separate sets of study results were presented, entitled respectively, “Alzheimer’s Patients Exhibit Defective Serum Ceruloplasmin Associated with Defective Copper Binding” and “Sub-Clinical Zinc Deficiency Found in Alzheimer’s Disease.”......
About Adeona Pharmaceuticals, Inc.
Adeona Pharmaceuticals, Inc. (AMEX:AEN - News) is a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of subclinical zinc deficiency and chronic copper toxicity in the mature population. Adeona believes that such conditions may contribute to the progression of debilitating degenerative diseases, including, Dry Age-Related Macular Degeneration (Dry AMD), Alzheimer's disease (AD) and mild cognitive impairment (MCI) in susceptible persons. Adeona is also developing a number of late-stage clinical drug candidates for the treatment of rheumatoid arthritis and multiple sclerosis... Adeona Pharmaceuticals' Press Release -
